Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Biden Vows to Fund Biotech to Fight Cancer on 60th "Moonshot
View:
Post by Noteable on Sep 14, 2022 12:23pm

Biden Vows to Fund Biotech to Fight Cancer on 60th "Moonshot

This POTUS committment to fund biotech to fight cancer comes at an optimal time for Big Pharma M&A activities going into 2023, for companies with emerging immuno-oncology agents such as ONCY's immune molecule platform in pelareorep.

https://www.biospace.com/article/biden-vows-to-fund-biotech-to-fight-cancer/
Comment by Buckhenry on Sep 14, 2022 1:08pm
Great... that is all we need is biden to fix this like he has the economy... we are doomed!!
Comment by Noteable on Sep 14, 2022 1:26pm
Last June, the FDA formally established the Center for Advancement of Manufacturing Pharmaceuticals and Biopharmaceuticals to improve collaboration between its two drug evaluation departments, one focused on traditional small-molecule and antibody drugs, and the other on live biotherapeutics and cell and gene therapies. Under the HHS plan, the FDA will also provide opportunities for ...more  
Comment by Noteable on Sep 14, 2022 6:53pm
https://www.whitehouse.gov/briefing-room/presidential-actions/2022/09/12/executive-order-on-advancing-biotechnology-and-biomanufacturing-innovation-for-a-sustainable-safe-and-secure-american-bioeconomy/
Comment by Buckhenry on Sep 14, 2022 10:13pm
I finally figured it out....notable must be a bot working for biden.
Comment by Lesalpes29 on Sep 15, 2022 6:00am
Westcoast did the right thing ... ignore you go bucky. I dont need to read your stupid stuff.
Comment by Noteable on Sep 15, 2022 7:04pm
One Democratic senator, Patty Murray of Washington state tweeted, “The [Republican party’s] cruel, dangerous laws are forcing doctors to delay treatment for cancer patients and making it harder for women to get the health care they need. The [Republican] agenda is putting everyone at risk.” Biden himself took a more diplomatic, but still political tack, saying, “Cancer does not discriminate ...more  
Comment by Noteable on Sep 15, 2022 7:16pm
September 15, 2022 -  Biden’s “Cancer Moonshot” Brings Biotech Focus Back to U.S. [ONCY's US head office is in San Diego California, and ONCY is registered in Delaware as a US company. And any Big Pharma company acquiring ONCY has the benefit of Biden's "Cancer Moonshot" funding because of ONCY's precison medicine focus and the advanced manufacturing component ...more  
Comment by Buckhenry on Sep 16, 2022 3:26pm
and you dont think what the biden administration has done has not put people at risk. some can't afford food now with the inflation. now who is lying folks??
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities